KVP Capital Advisors, LP

KVP Capital Advisors, LP reported 36 holdings worth US$124M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

KVP Capital Advisors, LP reported 36 holdings worth US$124M as of Sep 30, 2026. Largest: Praxis Precision Medicines, Inc., Whitehawk Therapeutics, Inc. and Silence Therapeutics PLC. Filed Nov 16, 2026 (Form 13F).

Holdings
36
Value as reported
US$124M

The filing in full

CompanySharesValue as reported% of portfolio
Praxis Precision Medicines, Inc.42,900US$12.5M10.1%
Whitehawk Therapeutics, Inc.2.17MUS$8.14M6.6%
Silence Therapeutics PLC684KUS$7.48M6.0%
Protagonist Therapeutics, Inc.53,000US$7.47M6.0%
MBX Biosciences, Inc.122KUS$7.12M5.7%
Erasca, Inc.455KUS$6.67M5.4%
Trevi Therapeutics, Inc.414KUS$5.93M4.8%
Tango Therapeutics, Inc.230KUS$5.75M4.6%
Edgewise Therapeutics, Inc.133KUS$5.4M4.3%
Tandem Diabetes Care, Inc.301KUS$4.91M3.9%
Achieve Life Sciences, Inc.462KUS$3.74M3.0%
Sutro Biopharma, Inc.227KUS$3.65M2.9%
Insmed Incorporated28,497US$3.25M2.6%
Savara, Inc.605KUS$3.12M2.5%
ArriVent BioPharma, Inc.102KUS$3.09M2.5%
IDEAYA Biosciences, Inc.79,700US$3.06M2.5%
Disc Medicine, Inc.43,750US$2.86M2.3%
United Therapeutics Corporation4,750US$2.57M2.1%
Viridian Therapeutics, Inc.125KUS$2.57M2.1%
Immix Biopharma, Inc.230KUS$2.4M1.9%
Design Therapeutics, Inc.185KUS$2.33M1.9%
Ocular Therapeutix, Inc.300KUS$2.3M1.9%
Travere Therapeutics, Inc.39,000US$2.3M1.8%
Mineralys Therapeutics, Inc.84,168US$2.12M1.7%
Vogenx Inc86,069US$1.96M1.6%
Nektar Therapeutics26,900US$1.63M1.3%
Bright Minds Biosciences Inc.31,813US$1.58M1.3%
Zura Bio Limited373KUS$1.55M1.2%
Artiva Biotherapeutics, Inc.200KUS$1.42M1.1%
Evolus, Inc. Common Stock150KUS$1.2M0.97%
Vera Therapeutics, Inc.32,700US$1.06M0.85%
Cabaletta Bio, Inc.505KUS$970K0.78%
Adial Pharmaceuticals, Inc210KUS$843K0.68%
Compass Therapeutics, Inc.771KUS$802K0.65%
Celcuity Inc.4,000US$318K0.26%
Axsome Therapeutics, Inc.0US$00.00%
Scholar Rock Holding Corporation0US$00.00%
VYNE Therapeutics Inc.0US$00.00%

Source

Download original · View original at SEC

Related